What a difference five years can make. Just look at Eli Lilly (NYSE: LLY). In April 2020, the drugmaker stood in the shadows ...

We recently published a list of 10 Firms End Stronger, Buck Muted Broader Market Trading. In this article, we are going to ...

Clonakility Distillery, dairy giant Ornua and machine-maker Edge Innovate in the crosshairs of disruptive policy programme ...

In an exclusive interview with NBC News' Stephanie Gosk, Eli Lilly's chief scientific officer says their weight loss pills ...

Eli Lilly reported promising results from a study of its experimental oral drug that could rival popular injections to treat ...

Eli Lilly said clinical results of its GLP-1 in pill form showed safety and efficacy data similar to blockbuster injectable ...

Eli Lilly and Co., the maker of Zepbound and Mounjaro, announced a successful Phase 3 trial for a once-daily GLP-1 pill for ...

Eli Lilly's experimental pill worked as well as blockbuster drug Ozempic to lower weight and blood sugar in a trial of ...

Zoom out: The positive results sent Lilly's stock soaring 16% Thursday to $852. Bank of America's Anderson projected 2030 ...

A daily pill from drugmaker Eli Lilly has shown safety results comparable to the leading injectable GLP-1 drugs Mounjaro and ...

In a trial, the daily GLP-1 pill showed "significant" results and similar side effects to injectable GLP-1 drugs like Ozempic and Mounjaro, the pharmaceutical company says.

If approved, the pill is expected to be far easier to administer than current injectables — and far easier to manufacture.